Abstract
Cyclosporine (CyA) is a immunosuppressive agent which has been used to a large number of children with nephrotic syndrome and transplantation. Therapeutic monitoring of this drug is essential because it has a narrow therapeutic window and inter-and intra-patient variability.
The new micro-emulsion pre-concentrate (MEPC) drug reduce variability, and therapeutic drug monitoring and target level of its concentration are reconsidered. A trough concentration (C0) has been commonly used for drug monitoring. However, in cases of renal transplantation, some reports suggest that the concentration of CyA 2hr after dosing (C2) or C3 correlates with area under the blood concentration curve. Our results also suggest that C2 monitoring may be a better method in frequently relapsing children with steroid-sensitive nephrotic syndrome. Our observation should be extent to a large population study.
